VP7 (31-40) Peptide corresponds to a defined epitope from the VP7 viral protein, containing polar and aromatic residues crucial for recognition. Researchers probe its conformational behavior to map antigenic surfaces. Applications include epitope characterization, peptide-protein binding studies, and structural immunology research.
CAT No: R2828
Synonyms/Alias:VP7 (31-40) peptide; HY-P5667; DA-68632; CS-0888982; 152687-39-3
VP7 (31-40) peptide represents a synthetic fragment derived from the highly conserved region of the rotavirus VP7 glycoprotein, a structural component essential for viral assembly and immune recognition. This decapeptide is meticulously designed to mimic a specific epitope within the VP7 protein, making it a valuable tool for research focused on virology, immunology, and molecular biology. Its defined sequence and structural fidelity provide researchers with a reliable reagent for mapping immune responses, studying protein-protein interactions, and exploring the molecular mechanisms underlying rotavirus infection. The peptide's solubility and stability in aqueous solutions further enhance its suitability for a wide range of laboratory applications, ensuring reproducible results in both in vitro and in vivo experimental systems. As a chemically synthesized molecule, VP7 (31-40) peptide offers batch-to-batch consistency, which is crucial for comparative studies and high-throughput analyses.
Epitope Mapping: VP7 (31-40) peptide is frequently employed in the precise identification of immunodominant regions within the rotavirus VP7 protein. By using this peptide in immunoassays such as ELISA or Western blot, researchers can pinpoint specific antibody binding sites, facilitating the characterization of humoral immune responses in infected hosts or vaccine recipients. Epitope mapping with this peptide aids in understanding antigenic variation and the development of broadly reactive antibodies, which are critical for advancing research on immune evasion and cross-protection among rotavirus strains.
Antibody Production: The peptide serves as an effective immunogen or antigen for generating polyclonal or monoclonal antibodies specific to the VP7 region. When conjugated to carrier proteins and administered in animal models, it stimulates the production of targeted antibodies that recognize the native VP7 protein. These antibodies are invaluable for downstream applications such as immunohistochemistry, immunoprecipitation, and diagnostic assay development, supporting the detection and quantification of rotavirus antigens in various biological samples.
Vaccine Research: VP7 (31-40) peptide is utilized in the evaluation of candidate vaccine formulations, particularly in the context of subunit or peptide-based strategies. By incorporating this epitope into vaccine constructs, researchers can assess its immunogenicity and ability to elicit protective immune responses in preclinical models. The peptide's defined sequence allows for controlled studies on immune recognition, adjuvant effects, and epitope presentation, providing insights that guide the rational design of next-generation rotavirus vaccines.
Protein-Protein Interaction Studies: The decapeptide is a valuable probe for investigating the molecular interactions between the VP7 protein and host cell factors during the rotavirus lifecycle. By using techniques such as surface plasmon resonance or pull-down assays, scientists can examine binding affinities, map interaction interfaces, and identify potential inhibitors that disrupt critical viral processes. These studies contribute to a deeper understanding of viral pathogenesis and the identification of novel antiviral targets.
Diagnostic Assay Development: The VP7 (31-40) fragment is integrated into various immunoassay platforms for the sensitive and specific detection of anti-rotavirus antibodies or antigens. Its use in assay calibration, validation, and quality control ensures high specificity and reproducibility, which are essential for reliable serological studies and epidemiological surveillance. The peptide's well-characterized sequence facilitates standardized assay development, supporting the monitoring of rotavirus infection rates and immune status in research settings.
Peptide-based structural studies: VP7 (31-40) peptide is also instrumental in elucidating the three-dimensional structure and conformational dynamics of the VP7 epitope. Through techniques such as nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography, researchers can analyze its secondary structure and interaction with antibodies or other binding partners. These structural insights are fundamental for understanding epitope accessibility, guiding rational antigen design, and advancing the field of structural vaccinology. The multifaceted applications of VP7 (31-40) peptide underscore its importance as a versatile reagent in virological, immunological, and biochemical research, supporting the discovery of novel therapeutic and preventive strategies against rotavirus and related pathogens.
1. High fat diet and GLP-1 drugs induce pancreatic injury in mice
3. Adipose tissue is a key organ for the beneficial effects of GLP-2 metabolic function
5. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More